MAPT and Alzheimer disease: We acknowledge the relatively small cohort size, short duration of follow up and the lack of more rigorous measures and biomarkers of AD, including cortical Aβ‐42 or tau PET, CSF Aβ‐42 or phosphorylated tau, CSF T‐tau or FDG PET hypometabolism.3